• Opublikowano: 25/03/2020

Medical University of Lodz ranked number 1 in the first call of the Medical Research Agency (Poland)

Two out of 7 applications submitted by Medical University of Lodz in the first call of the Medical  Research  Agency  (ABM) were evaluated positively and received funding.

The total amount awarded to Medical University of Lodz exceeds 44 MLN PLN. 

Project “Childhood ALL in Poland (cALL-POL): national harmonization of diagnosis and treatment of acute lymphoblastic leukemia in children”, coordinated by prof. Wojciech Młynarski – Head of the Pediatrics, Oncology and Hematology Clinic, has been awarded 1st place in the ranking list among 77 submitted applications. The project will be implemented in cooperation with the Medical University of Silesia, the Central Clinical Hospital of the Medical University of Lodz, the Medical University of Lublin and the Institute of Innovative Technologies EMAG, acting jointly as part of an emerging scientific consortium. The main objective of cALL-POL is to facilitate an access to the most advanced treatment regimens for Polish children with Acute Lymphoblastic Leukemia (ALL) and to identify treatment options for the patients who did not respond to standard therapeutic strategy using an advanced genome-wide molecular search. All Polish pediatric oncology centers will become clinical partners in the project. The cALL-POL consortium will be connected to the iBFM network, which is one of the world’s largest international clinical research networks in the field of leukemia and lymphoma in children. Patients with newly diagnosed Acute Lymphoblastic Leukemia (ALL) will have a chance to participate in three different controlled clinical trials. Project funding amounts to 28 MLN PLN.

The second project, which has gained the favor of Medical Research Agency experts, is a study coordinated by prof. Joanna Narbutt, Department of Dermatology, Pediatric and Oncological Dermatology entitled “A randomized, double-blind, placebo-controlled phase III study in children evaluating the efficacy and safety of methotrexate and ciclosporin in patients with moderate to severe AD”. Study is addressing needs of population (total n = 317) between 2 and 18 years of age, with moderate to severe atopic dermatitis (AD), not responding to local treatment and requiring general therapy. The project will be implemented in a single-center mode with funding of over 16 MLN PLN Congratulations to the winners of the first Medical Research Agency call for non-commercial trials !!


Medical University of Lodz
Al. Kościuszki 4
90-419 Łódź
NIP 725 18 43 739
REGON 473 073 308

Find us!